Prothena (STU:0PT) Research & Development: €83.16 Mil (TTM As of Mar. 2026)


STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €8.72
GF Value €12.85
! 3 Warning Signs
View Full Analysis

What is Prothena Research & Development?

Prothena STU:0PT +6.34% 74 Research & Development is €83.16 Mil as of Mar. 2026. GuruFocus rates STU:0PT with a GF Score™ of 74/100 and a GF Value™ of €12.85. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Prothena's Research & Development for the three months ended in Mar. 2026 was €10.92 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €83.16 Mil.

Prothena  (STU:0PT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prothena Research & Development Related Terms

Prothena Research & Development Historical Data

* Premium members only.

The historical data trend for Prothena's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena Research & Development Chart

Prothena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.82 127.97 202.26 212.51 115.16

Prothena Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.00 35.13 24.66 12.46 10.92
STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prothena Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €83.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €83.16 Mil mean?
Prothena (STU:0PT) has a Research & Development of €83.16 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Prothena and its competitors.
Is Prothena's Research & Development too high?
Prothena's current Research & Development is €83.16 Mil. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Research & Development compare to EDIT and ACHV?
Prothena's Research & Development of €83.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Prothena and its competitors. Prothena's current Research & Development is €83.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current Research & Development of €83.16 Mil. The stock's GF Value™ is €12.85, compared to a current price of €8.72 — trading 32.2% below its estimated fair value. The current Research & Development is €83.16 Mil. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Prothena (STU:0PT), the current Research & Development is €83.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €8.72 is trading 32.2% below its estimated GF Value™ of €12.85.

Key valuation signals for STU:0PT:

  • Research & Development: €83.16 Mil
  • GF Value™: €12.85 vs. price of €8.72 (32.2% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.72
Price
€12.85
GF Value